MRKMerck & Co., Inc.
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- $2.49Beat
- vs $2.12 expected on Oct 29
- Stock move on it
- +3.83%
- one session
- Typical move
- ±2.0%
- average over 2 reports
- Price
- $146.96
- −0.15% today · $322B cap
Past and upcoming reports
2
| Oct 29, 2026 | Sep 30, 2026 | Time not given | $2.12 | Beat$2.49 | +3.83% |
| Aug 4, 2026 | Jun 30, 2026 | Time not given | −$0.26 | Beat−$0.13 | +0.18% |
After the report
Aug 4, 2026 report
This covers the Aug 4, 2026 report. The Oct 29, 2026 numbers are in the table above.
Merck beat quarterly EPS estimates, while raised outlook and new-drug adoption supported the longer-term thesis.
Merck reported -$0.13 EPS versus -$0.26 estimated, a 50% beat, and shares were up 0.16% at $128.57 on August 7.
Reported against expected
BeatReported EPS was -$0.13 for the quarter ended June 30, versus -$0.26 estimated. the $0.13 difference represented a 50% beat.
Guidance
RaisedManagement raised its outlook, but the payload provides no numerical guidance figures.
How the stock reacted
The event-day, first-day, and second-day reactions are unknown. shares were up 0.16% to $128.57 on August 7, with 5.07 million shares traded.
What changed
EPS was -$0.13 versus -$0.26 expected, while management raised its outlook and highlighted new-drug adoption.
What the price now assumes
The $128.57 price reflects limited immediate reaction, despite a 36.19 trailing P/E and 13.31 forward P/E.
What it means for the business
Maintain a constructive bias. upgrade only if new medicines measurably offset KEYTRUDA risk over the next 90 days.
The next one to three months, as we saw it then
Better case33%
Raised outlook and approvals support continued multiple tolerance if new-drug adoption demonstrates replacement growth for slowing KEYTRUDA.
Base case34%
The EPS beat supports earnings stability, but weak 2.7% TTM revenue growth and 6.0% five-year EPS growth limit near-term rerating.
Worse case33%
Investors may de-rate Merck if the EPS beat proves temporary and newer medicines do not replace slowing KEYTRUDA revenue.
If you hold it
Hold unless management weakens the raised outlook or new-drug adoption fails to offset KEYTRUDA pressure within 90 days.
If you are watching
Enter only if new-drug adoption is shown to offset slowing underlying growth. do not trade if guidance remains numerically unavailable and the replacement-growth evidence is unchanged.
Scenario odds are a judgement, not measured.